Caroline J Breitbach
Overview
Explore the profile of Caroline J Breitbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park S, Breitbach C, Lee J, Park J, Lim H, Kang W, et al.
Mol Ther
. 2015 Jun;
23(9):1532-40.
PMID: 26073886
Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells....
12.
Breitbach C, Moon A, Burke J, Hwang T, Kirn D
Methods Mol Biol
. 2015 Jun;
1317:343-57.
PMID: 26072416
Primary liver cancer (hepatocellular carcinoma; HCC) in patients not eligible for surgery or transplant is currently treated by locoregional therapeutic approaches, including trans-arterial chemoembolization and radiofrequency ablation. Sorafenib (Nexavar; Bayer/Onyx)...
13.
Burke J, Nieva J, Borad M, Breitbach C
Curr Opin Virol
. 2015 May;
13:55-60.
PMID: 25989094
Developing a live anti-cancer agent derived in most cases from human pathogens presents a unique set of challenges to clinical development versus those anticipated with standard chemotherapeutics and small molecules....
14.
Breitbach C, Parato K, Burke J, Hwang T, Bell J, Kirn D
Curr Opin Virol
. 2015 Apr;
13:49-54.
PMID: 25900822
Oncolytic immunotherapies (OI) selectively infect, amplify within and destroy cancer cells, thereby representing a novel class of anti-cancer therapy. In addition to this primary mechanism-of-action (MOA), OI based on vaccinia...
15.
Evgin L, Acuna S, de Souza C, Marguerie M, Lemay C, Ilkow C, et al.
Mol Ther
. 2015 Mar;
23(6):1066-1076.
PMID: 25807289
Oncolytic viruses (OVs) have shown promising clinical activity when administered by direct intratumoral injection. However, natural barriers in the blood, including antibodies and complement, are likely to limit the ability...
16.
Cripe T, Ngo M, Geller J, Louis C, Currier M, Racadio J, et al.
Mol Ther
. 2014 Dec;
23(3):602-8.
PMID: 25531693
Pexa-Vec (pexastimogene devacirepvec, JX-594) is an oncolytic and immunotherapeutic vaccinia virus designed to destroy cancer cells through viral lysis and induction of granulocyte-macrophage colony-stimulating factor (GM-CSF)-driven tumor-specific immunity. Pexa-Vec has...
17.
Zeh H, Downs-Canner S, McCart J, Guo Z, Rao U, Ramalingam L, et al.
Mol Ther
. 2014 Oct;
23(1):202-14.
PMID: 25292189
Oncolytic viral therapy utilizes a tumor-selective replicating virus which preferentially infects and destroys cancer cells and triggers antitumor immunity. The Western Reserve strain of vaccinia virus (VV) is the most...
18.
Lichty B, Breitbach C, Stojdl D, Bell J
Nat Rev Cancer
. 2014 Jul;
14(8):559-67.
PMID: 24990523
Recent clinical data have emphatically shown the capacity of our immune systems to eradicate even advanced cancers. Although oncolytic viruses (OVs) were originally designed to function as tumour-lysing therapeutics, they...
19.
Moehler M, Goepfert K, Heinrich B, Breitbach C, Delic M, Galle P, et al.
Front Oncol
. 2014 May;
4:92.
PMID: 24822170
Human tumors develop multiple strategies to evade recognition and efficient suppression by the immune system. Therefore, a variety of immunotherapeutic strategies have been developed to reactivate and reorganize the human...
20.
Kim M, Breitbach C, Moon A, Heo J, Lee Y, Cho M, et al.
Sci Transl Med
. 2013 May;
5(185):185ra63.
PMID: 23677592
Oncolytic viruses cause direct cytolysis and cancer-specific immunity in preclinical models. The goal of this study was to demonstrate induction of functional anticancer immunity that can lyse target cancer cells...